CoChat
Sign Up
Cited by 115Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD

Koren, Michael J., Davidson, Michael H., Wilson, Daniel J., Fayyad, Rana S., Zuckerman, Andrea, Reed, David P.·2009·American Journal of Kidney Diseases
DOI 10.1053/j.ajkd.2008.11.025
Open this paper in CoChat — free account

Abstract

Background This post hoc analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study investigates the effect of focused atorvastatin therapy versus usual care on cardiovascular outcomes in patients with coronary heart disease (CHD) with and without chronic kidney disease (CKD).Study design Prospective randomized open-label; median follow-up, 54.3 months.Setting & participants Managed care or Veterans Affairs facilities; 2,442 patients with CHD with dyslipidemia; mean age, 61.6 years.Intervention Focused atorvastatin therapy to a low-density lipoprotein cholesterol goal of less than 80 mg/dL or maximum dose of 80 mg/d versus usual care as deemed appropriate by patients' regular physicians.Predictor Baseline estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study equation of less than 60 mL/min/1.73 m(2) (patients with CKD) and 60 mL/min/1.73 m(2) or greater (patients without CKD).Outcomes & measurements The primary end point was time to first cardiovascular event. Change from baseline eGFR was assessed in 1,768 patients with follow-up renal data.Results At baseline, 579 patients (23.7%) had CKD: 31.6% of these patients experienced a primary cardiovascular event during the study versus 23.6% of patients without CKD (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.18 to 1.68; P < 0.001). Compared with usual care, atorvastatin therapy reduced the relative risk of a primary outcome by 28% in patients with CKD (HR, 0.72; 95% CI, 0.54 to 0.97; P = 0.02) and 11% in patients without CKD (HR, 0.89; 95% CI, 0.74 to 1.07; P = 0.3) (P for treatment by CKD interaction = 0.2). There was no decrease in eGFR in atorvastatin-treated patients during the course of the study.Limitations Follow-up of atorvastatin patients was restricted to every 6 months; interim data were unavailable for usual-care patients.Conclusions Patients with CHD and CKD are at increased risk of cardiovascular events. Compared with usual care, focused atorvastatin treatment decreased cardiovascular risk for established patients in real-world settings, with no significant difference in treatment effects observed between patients with and without CKD.

Overview

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2008.11.025

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

Sorted by citations

See all 115

Related

Metadata

Authors
Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P.
Affiliations
  • Jacksonville Center for Clinical Research (US)
  • University of Chicago (US)
  • Pfizer (United States) (US)
Corresponding author
Koren, Michael J.
ORCID
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2009-05
Volume
53
Issue
5
Pages
741-750
ISSN
0272-6386 (ISSN-L)
DOI
10.1053/j.ajkd.2008.11.025
OpenAlex
W1979397038
Cited by
115
References
28
Citations by year
2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 8 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 12
FWCI
12.14
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • American Journal of Kidney Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
atorvastatin, coronary artery disease, chronic kidney disease, LDL cholesterol lowering, cardiovascular events, estimated glomerular filtration rate, statin therapy, managed care, dyslipidemia, renal safety, veterans, cardiovascular risk reduction, renal function preservation, cardiovascular risk stratification
MeSH terms
Atorvastatin, Aged, Coronary Disease, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Glomerular Filtration Rate, Health Maintenance Organizations, Heptanoic Acids, Humans, Kidney Failure, Chronic, Cholesterol, LDL, Male, Middle Aged, Prospective Studies, Pyrroles, Time Factors, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review